The facts
Inceptive at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- Palo Alto, United States
- Founded
- 2021Inceptive homepage (company)
- Last closed-round valuation
- No valuation reported
- What it has shipped
- Research only so far
Founders
- Jakob Uszkoreit: co-founder and CEO; one of eight authors of the 2017 Transformer paper while a software engineer at Google (Crazy Stupid Tech (newsletter), Jan 12, 2025)
- Rhiju Das: Stanford biochemistry professor (Crazy Stupid Tech (newsletter), Jan 12, 2025)
Alnylam collaboration on RNAi therapeutics valued at up to $2 billion, with $30 million upfront including an equity purchase. Jun 3, 2026
Inceptive (company blog), Jun 3, 2026
What it has built
Shipped, or not yet.
“Research only so far” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
Blog: from better models to better in vivo CAR-T
Source1 round
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Jan 12, 2025 | Two early rounds (cumulative, as reported) | about $120 million committed | Not stated | Andreessen Horowitz, Obvious Ventures, Section 32, Nvidia | Crazy Stupid Tech (newsletter) |
Our note
Worth knowing.
Our note: Funding figure comes from a tech newsletter (Crazy Stupid Tech), not a listed trusted outlet, and has no round dates; the company site names backers but no amounts. No product, peer-reviewed paper or trial registry entry found. Offices in Palo Alto, Berlin and Zurich.
More drug discovery and biology